About FARCO-PHARMA
FARCO-PHARMA is a Healthcare company based in Koln (Germany) founded in 1964. It develops and distributes sterile gels and instillation therapies for urology. It operates on a B2B model. FARCO-PHARMA has completed 1 acquisition, including Purenum. FARCO-PHARMA offers products and services including Instillagel, Hydrogel-Methode, VESOXX, Farco-fill, and Deflux. Its focus areas include Urology, Medical Devices, Sterile Lubricants and Therapies. Its legal entity is FARCO-PHARMA GmbH. Its competitors include Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
FARCO-PHARMA GmbH specializes in manufacturing and supplying sterile lubricants, instillation therapies, and medical devices for urological procedures. Based in Germany, they focus on quality products like Instillagel and Hydrogel-Methode, serving healthcare providers and patients through distribution networks. The company engages in events, educational resources, and global partnerships to support urological care and innovation.
- Investments & Acquisitions
Products & Services of FARCO-PHARMA
FARCO-PHARMA offers a comprehensive portfolio of products and services, including Instillagel, Hydrogel-Methode, VESOXX, Farco-fill, and Deflux.
Sterile lubricant for urological procedures and examinations
Hydrogel-based treatment for urological conditions
Solution for managing urological issues
Injection solution for medical applications
Injection for urological treatments
Investments & Acquisitions by FARCO-PHARMA
FARCO-PHARMA has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Purenum.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biocompatible adhesives for kidney stone fragment removal are developed. | purenum.com | Bremen, Germany | 2017 | Jun 2023 | •••• |
Complete acquisition details for FARCO-PHARMA
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of FARCO-PHARMA
2 dated milestones of FARCO-PHARMA across 59 years, from founding to its latest funding, stage changes and deals.
- Founded FARCO-PHARMA is founded.
- Acquisition Acquires Purenum.
Competitors of FARCO-PHARMA
FARCO-PHARMA has 10 listed competitors in our database, 8 of them funded. They include Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lipella.com | 2005 | Pittsburgh, United States | $3.37M | 5 | Lipid-based therapies for common bladder syndromes are developed. | |
| theravida.com | 2005 | San Mateo, United States | $12.5M | – | Clinical stage biopharma company developing drugs for urology and central nervous system disorders | |
| espritpharma.com | 2005 | East Brunswick, United States | $219.49M | – | Develop drugs for genitourinary (GU) disorders | |
| regenephro.co.jp | 2019 | Kyoto, Japan | $28.88M | – | Developer of therapeutics to treat renal diseases | |
| kissei.co.jp | 1946 | Matsumoto, Japan | – | – | Therapies for renal diseases and urology-related anemia are developed. | |
| aceruspharma.com | 2008 | Mississauga, Canada | $38.07M | – | Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments. | |
| urovant.com | 2017 | Irvine, United States | – | – | Therapies for urological disorders such as overactive bladder are developed. | |
| ixchelsis.com | 2011 | Sandwich, United Kingdom | $26M | 4 | Develops oxytocin receptor antagonists for treating genitourinary disorders. | |
| urigen.com | 1997 | North Brunswick, United States | $3.02M | – | Pain relief products for urological ailments are developed and tested. | |
| ixaltis.com | 2012 | Toulouse, France | $8.89M | – | Therapeutics for genito-urinary diseases including stress urinary incontinence are developed. |
Detailed competitors of FARCO-PHARMA
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genitourinary Disorders
10 companies that operate in the same segment as FARCO-PHARMA (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Farco-Pharma
Complete news archive for FARCO-PHARMA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about FARCO-PHARMA
FARCO-PHARMA was founded in 1964.
FARCO-PHARMA is headquartered in Koln, Germany. It is registered at Koln, North Rhine-westphalia, Germany.
FARCO-PHARMA GmbH specializes in manufacturing and supplying sterile lubricants, instillation therapies, and medical devices for urological procedures. Based in Germany, they focus on quality products like Instillagel and Hydrogel-Methode, serving healthcare providers and patients through distribution networks. The company engages in events, educational resources, and global partnerships to support urological care and innovation.
FARCO-PHARMA's top competitors include Lipella, Kissei Pharmaceutical and Regenfro Co.
FARCO-PHARMA offers Instillagel, Hydrogel-Methode, VESOXX, Farco-fill, and Deflux.
FARCO-PHARMA has made 1 acquisition, including Purenum.
FARCO-PHARMA operates through Farco-Pharma Gmbh.